Joanna Triscott

(1/10) Very pleased to announce our newest publication is now online at Molecular Cancer Research! @MarkARubin1 @MCR_AACR @AACR aacrjournals.org/mcr/article/do…

@PCaParker @NimaSharifiMD @Rainmaker1973 We also had a follow-up paper. Mouse model in Fig 5 surprised us. aacrjournals.org/mcr/article/23…

@NimaSharifiMD @Rainmaker1973 @JoTriscott Thanks very much

Scientists have identified a single enzyme that acts as the “Achilles’ heel” of prostate cancer — and developed a way to shut it down without harming healthy tissue. The enzyme, known as PI5P4Kα, fuels tumor cell growth and resistance to chemotherapy. By blocking it, researchers found that cancer cells rapidly self-destruct due to energy starvation, while normal cells remain untouched. This targeted approach is a major leap beyond radiation or chemo, which damage healthy tissue and cause severe side effects. The treatment uses precision inhibitors, tiny molecules that lock onto the enzyme’s active site, effectively turning off the tumor’s power supply.

In memory of Dr. Felix Feng. Thank you @EUplatinum for honoring our beloved colleague and friend, gone too soon. We miss you Felix @MaryFengMD @nlinmd @PCF_Science sciencedirect.com/science/articl…

Loss of Pi5P4Ka slows the progression of Pten mutant basal cell model of prostate cancer. @JoTriscott; Marika Lehner; @AndrejBenjak; Matthias Reist; BrookeM Emerling; Charlotte K.Y.Ng; @Simone de Brot; @MarkARubin1 tinyurl.com/48muj6zn

A great Pleasure to Present our paper on Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇👇👇👇👇👇👇👇 sciencedirect.com/science/articl… The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where high-quality evidence is still lacking. The conference gathered expert opinions on controversial clinical issues, particularly in advanced prostate cancer, offering guidance in cases where guidelines are unclear or conflicting. The report emphasizes personalized treatment approaches, considering patient-specific factors and evolving clinical data, and stresses the importance of ongoing clinical trials to fill knowledge gaps. It provides a practical framework for physicians and patients to engage in shared decision-making, especially in complex cases of high-risk localized and locally advanced prostate cancer. Our Thanks to all authors: @Silke_Gillessen @fabioturco92 @Prof_IanD @drjefstathiou Karim Fizazi @Prof_Nick_James Neal Shore Eric Small Matthew Smith @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims Emmanuel S. Antonarakis Ana Aparicio Andrew J. Armstrong Diogo Assed Bastos Gerhardt Attard Karol Axcrona Mouna Ayadi Himisha Beltran @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti Muhammad Bulbul Consuelo Buttigliero Orazio Caffo @cdanicas @Ecastromarcos Heather H. Cheng Kim N. Chi Caroline S. Clarke Noel Clarke Johann S. de Bono @mdesantis234 @nachoduranm @EfstathiouEleni Onyeanunam N. Ekeke Tamer I.H. El Nahas @drlouiseemmett @stefanofanti4 Omolara A. Fatiregun Felix Y. Feng Peter C.C. Fong @fontev1 @Nicola_Fossati Daniel J. George @marty_gleave Gwenaelle Gravis Susan Halabi Daniel Heinrich @ProfKHerrmann @DrMHofman Thomas A. Hope Lisa G. Horvath Maha H.A. Hussain @BarbaraJereczek Robert J. Jones Anthony M. Joshua @ravikanesvaran Daniel Keizman @FacsRaja Gero Kramer @LoebStacy Brandon A. Mahal Fernando C. Maluf 75 76, @quimmateo David Matheson 78, Mika P. Matikainen 79, Ray McDermott 80, @DrRanaMcKay Niven Mehra 82, @amerseburger @CaPsurvivorship , Michael J. Morris 85, Hind Mrabti 86, Deborah Mukherji @declangmurphy Vedang Murthy Shingai B.A. Mutambirwa @DrPaulNguyen William K. Oh @piet_ost Joe M. O’Sullivan Anwar R. Padhani Chris Parker Darren M.C. Poon Colin C. Pritchard Danny M Rabah Dana Rathkopf Robert E. Reiter Raphaele Renard-Penna Charles J. Ryan Fred Saad Juan Pablo Sade Shahneen Sandhu Oliver A. Sartor Edward Schaeffer Howard I. Scher Nima Sharifi Iwona A. Skoneczna Howard R. Soule @DrSpratticus Sandy Srinivas @cnsternberg Hiroyoshi Suzuki Mary-Ellen Taplin Camilla Thellenberg-Karlsson Derya Tilki Levent N. Türkeri Hiroji Uemura @DrYukselUrun Claire L. Vale Neha Vapiwala Jochen Walz Kosj Yamoah Dingwei Ye Evan Y. Yu Almudena Zapatero @AOmlin

(10/10)... and final thanks to the community of editors, reviewers, and researchers around the world who are working hard to make a difference for cancer patients🤗

(9/10) Massive thank you to all the coauthors: Marika Lehner, @AndrejBenjak, Matthias Reist, @BrookeEmerling, Charlotte Ng, simone de Brot….. and much gratitude for the support from @snsf_ch, @DBMR_Unibe, Fondation Johanna Dürmüller Bol.. And anyone we missed!

(1/10) Very pleased to announce our newest publication is now online at Molecular Cancer Research! @MarkARubin1 @MCR_AACR @AACR aacrjournals.org/mcr/article/do…

@MarkARubin1 @MountSinaiAlum Well deserved! Great work Gabriela.. and congrats Mark!😃🥳🥳

Great honor tonight from @MountSinaiAlumMount Association. Especially want to thank my beloved wife Gabriela ❤️for supporting me every day through 9 time zones.@MountSinaiAlum

Probably the best current review on PSMA expression ... congrats to @mishabeltran @mkbakht nature.com/articles/s4158…

Rare histologic transformation of a CTNNB1 (β-catenin) mutated #prostatecancer. The challenge of treatment selected lineage plasticity @PCFnews @DBMR_UniBe bit.ly/4cfvDOZ

A moderate increase in RagC GTPase signaling drives parenchymal damage, attracting myeloid cells that worsen damage in a 2-step pro-aging vicious cycle. nature.com/articles/s4358…

@wcandillon @Mind_Essentials @wcandillon the best..🤯🫶

@Mind_Essentials @JoTriscott ☺️

So exciting to see PI5P in the spotlight! Congrats to the entire team! 🥳